Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Significant Growth in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 114,600 shares, an increase of 165.9% from the February 28th total of 43,100 shares. Based on an average trading volume of 331,200 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are sold short.

Chugai Pharmaceutical Price Performance

CHGCY traded down $0.18 during midday trading on Tuesday, reaching $22.71. 241,235 shares of the company's stock were exchanged, compared to its average volume of 196,716. Chugai Pharmaceutical has a 1-year low of $14.52 and a 1-year high of $27.19. The stock has a market capitalization of $74.73 billion, a PE ratio of 29.49 and a beta of 0.77. The business's 50-day moving average price is $23.19 and its 200 day moving average price is $22.89.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, analysts expect that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.